Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Opinion|Videos|July 2, 2025
Reshaping Rx: Navigating 2025 Drug Pricing Policies—Recording
Author(s)Laura Joszt, MA
Fact checked by: Maggie L. Shaw
In a webinar, panelists discuss Trump's 2025 drug pricing policies, focusing on the Most Favored Nation order, pharmacy benefit manager reform, and implications for manufacturers and patients.
Advertisement
Advertisement
During a conversation on the Trump administration’s 2025 drug pricing policies, panelists discussed the implications of the Most Favored Nation policy, the broader context of drug pricing reforms, and efforts to address pharmacy benefit manager (PBM) reform through greater transparency.
Related to this article
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Cost and access, not side effects, drive GLP-1 discontinuation, and obesity should be covered like diabetes, says Fatima Cody Stanford, MD.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
Advertisement
Advertisement